ALNYLAM PHARMACEUTICALS, INC.
(NASDAQ: ALNY)
Balfour Capital Group has issued a buy recommendation for Alnylam Pharmaceuticals, Inc. (ALNY) on Nov. 26th, 2023.
Alnylam Pharmaceuticals, Inc., founded in 2002 and headquartered in Cambridge, Massachusetts, is an American biopharmaceutical company specializing in RNA interference (RNAi) therapeutics for genetically defined diseases. In 2016, Forbes recognized it as one of the “100 Most Innovative Growth Companies.”
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $162.98 on November 26th, 2023.
- Our designated price target stands at $300.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Alnylam Pharmaceuticals, Inc. (ALNY) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
